The First Biosimilar for Biologics in Allergy: CT ‐ P39 (Omlyclo‐Omalizumab‐Igec) Is Available for Asthma, Chronic Spontaneous Utricaria, and Chronic Rhinosinusitis With Nasal Polyps

Key Points

The aim is to evaluate the availability of CT-P39, a biosimilar treatment, for allergic conditions like asthma and chronic urticaria.
No datasets generated or analyzed.
Focus on the biosimilar CT-P39 (Omlyclo-Omalizumab-Igec) for specific allergies.
Assess the implications of availability for treatment options.
CT-P39 is now available for treating asthma, chronic spontaneous urticaria, and chronic rhinosinusitis with nasal polyps.
Marks a significant development in biosimilar medications for allergies.

Shows availability of a new biosimilar treatment for asthma and chronic allergic conditions, indicating potential benefits.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Klimek et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share